Related Experiment Video
Updated: Mar 16, 2026
Live Imaging Assay for Assessing the Roles of Ca2+ and Sphingomyelinase in the Repair of Pore-forming Toxin Wounds
Published on: August 25, 2013
Oral ulcer by Sphingomonas paucimobilis: first report
A Santarelli1, M Mascitti2, R Galeazzi3
1Department of Clinical Specialistic and Stomatological Sciences, Polytechnic Marche University, Ancona, Italy; Dental Clinic, Institute of Health and Research on Ageing, INRCA, Ancona, Italy.
This study reports the first oral infection caused by Sphingomonas paucimobilis in a patient with a gingival ulcer. This finding highlights Sphingomonas paucimobilis as an emerging oral pathogen, posing diagnostic and therapeutic challenges.
Area of Science:
- Oral Medicine
- Infectious Diseases
- Microbiology
Background:
- Sphingomonas paucimobilis is a Gram-negative bacterium.
- Initially reported in leg ulcers, S. paucimobilis infections are increasingly documented.
- The oral cavity is an under-recognized site for S. paucimobilis infections.
Observation:
- A 73-year-old male presented with a painful gingival ulcer and fever.
- The ulcer involved attached gingiva in the anterior maxilla with exposed bone.
- The patient's symptoms suggested a significant oral infection.
Findings:
- This case represents the first documented oral infection by Sphingomonas paucimobilis.
- The bacterium was identified as the causative agent of the gingival ulcer.
- The clinical presentation included pain during mastication and systemic fever.
Implications:
- Sphingomonas paucimobilis should be considered an emerging pathogen in oral infections.
- Non-classical oral pathogens present diagnostic and therapeutic challenges.
- Further research is needed to understand the prevalence and management of S. paucimobilis oral infections.
Related Concept Videos
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...